NCT05211024View on ClinicalTrials.gov

A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)

CompletedOBSERVATIONAL
Enrollment

1,423

Participants

Timeline

Start Date

January 28, 2022

Primary Completion Date

March 30, 2024

Study Completion Date

April 30, 2024

Conditions
Rheumatic Heart Disease
Interventions
DRUG

Penicillin G Benzathine

Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care

Trial Locations (1)

Unknown

Uganda Heart Institute, Kampala

Sponsors
All Listed Sponsors
collaborator

Uganda Heart Institute

OTHER

collaborator

Murdoch Childrens Research Institute

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER